Skip to main content

Rexahn-Pharmaceuticals-logo

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced that it has distributed to shareholders a mid-year update letter reviewing the company’s recent progress and clinical plans for the remainder of 2018 and 2019.

{iframe}http://investors.rexahn.com/news-releases/news-release-details/rexahn-issues-mid-year-shareholder-letter-review-recent-progress{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.